ProQR Therapeutics N.V.

corporate_fare Company Profile

ProQR Therapeutics N.V.

PRQR·NASDAQ·Life Sciences·CIK 0001612940

ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on discovering and developing new therapeutic medicines. The company develops an RNA editing platform using its Axiomer RNA editing technology, aimed at treating genetic disorders where current treatments are insufficient. Its primary product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. ProQR also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. The company has a research and collaboration agreement with Eli Lilly and Company to discover, develop, and commercialize potential new medicines for genetic disorders affecting the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics N.V. (NASDAQ:PRQR) is a publicly traded company in the Life Sciences sector. Wiseek monitors PRQR SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

ProQR Reports EUR0.40 Loss Per Share for 2025 (2026-03-12)
ProQR Reports Increased 2025 Net Loss, €92.4M Cash with Runway into Mid-2027, Advances Key Pipeline Programs (2026-03-12)
Major Investor Van Herk Increases Stake in ProQR Therapeutics to 14.6% with $2.15M Share Purchase (2026-02-06)
ProQR Reports Encouraging AX-0810 Phase 1 Safety Data, Advances Pipeline with Strong Preclinical Results, and Secures $4.5M Lilly Milestones (2026-01-08)

Financial Snapshot

Fiscal year ended December 31, 2025

Revenue

€15.91M EUR

Net Income

-€42.18M EUR

Diluted EPS

-€0.40 EUR

Op. Cash Flow

-€52.79M EUR

Free Cash Flow

-€53.81M EUR

Operating Income

-€43.45M EUR

Cash & Equivalents

€92.41M EUR

Debt / Equity

0.00×

Net Margin

-265.2%

Source: 20-F · filed 2026-03-12 · accession 0001104659-26-026713

Insider Transactions

PRQR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

show_chartPrice Chart

Loading chart...

feed PRQR - Filings & News (Page 2)

Filing Type

Date Range

PRQR

Mar 12, 2026, 7:02 AM EDT

Source: Dow Jones Newswires

Importance Score:

ProQR Reports EUR0.40 Loss Per Share for 2025

Price at Filing: $1.78

Real-time Price: $1.71

Change: -$0.070 (-4%)

Market Cap: $243.034M

Sentiment: Negative

View Wiseek Article

PRQR

Mar 12, 2026, 7:00 AM EDT

Filing Type: 6-K

Importance Score:

ProQR Reports Increased 2025 Net Loss, €92.4M Cash with Runway into Mid-2027, Advances Key Pipeline Programs

Price at Filing: $1.78

Real-time Price: $1.71

Change: -$0.070 (-4%)

Market Cap: $243.034M

Sentiment: Neutral

View Wiseek Article

PRQR

Feb 06, 2026, 4:01 PM EST

Filing Type: SCHEDULE 13D/A

Importance Score:

Major Investor Van Herk Increases Stake in ProQR Therapeutics to 14.6% with $2.15M Share Purchase

Price at Filing: $1.50

Real-time Price: $1.71

Change: +$0.210 (+14%)

Market Cap: $243.034M

Sentiment: Positive

View Wiseek Article

PRQR

Jan 08, 2026, 8:08 AM EST

Filing Type: 6-K

Importance Score:

ProQR Reports Encouraging AX-0810 Phase 1 Safety Data, Advances Pipeline with Strong Preclinical Results, and Secures $4.5M Lilly Milestones

Price at Filing: $2.29

Real-time Price: $1.71

Change: -$0.580 (-25%)

Market Cap: $243.034M

Sentiment: Positive

View Wiseek Article

corporate_fare Company Profile